CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
CVM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.02%73.340.9%$603.58m
CELGCelgene Corporation
2.24%130.291.1%$443.49m
AMGNAmgen Inc.
1.14%170.071.1%$408.88m
BIIBBiogen Inc.
1.26%286.721.2%$356.69m
REGNRegeneron Pharmaceuticals, Inc.
1.90%478.652.7%$320.91m
VRTXVertex Pharmaceuticals Incorporated
4.34%155.481.9%$240.46m
ALXNAlexion Pharmaceuticals, Inc.
3.58%138.201.9%$220.20m
ILMNIllumina, Inc.
2.14%194.763.5%$214.91m
INCYIncyte Corporation
2.46%123.862.6%$133.37m
KITEKite Pharma, Inc.
1.52%135.9516.1%$128.55m
CLVSClovis Oncology, Inc.
1.24%72.0818.0%$127.98m
TSROTESARO, Inc.
1.48%120.6214.7%$126.99m
AAgilent Technologies, Inc.
1.93%62.931.5%$121.42m
BMRNBioMarin Pharmaceutical Inc.
1.07%81.464.4%$105.18m
SRPTSarepta Therapeutics, Inc.
3.41%36.9519.8%$99.21m

Company Profile

CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.